Aspira Women's Health (AWHL) director granted option for 314,811 shares

Rhea-AI Filing Summary

Aspira Women's Health Inc.12/02/2025, the reporting person received a stock option, described as a right to buy up to 314,811 shares of the company’s common stock at an exercise price of $0.35 per share. The option becomes exercisable on the same date, 12/02/2025, and is scheduled to expire on 12/02/2035.

Following this grant, the reporting person beneficially owns 314,811 derivative securities directly in the form of this stock option. The form is signed by /s/ John D. Fraser, indicating his role as the reporting person and confirming the director status in relation to Aspira Women's Health.

12/04/2025 - 08:33 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fraser John D

(Last) (First) (Middle)

C/O ASPIRA WOMEN'S HEALTH INC

12117 BEE CAVES RD, BLDG 3-100

(Street)

AUSTIN, TX 78738

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aspira Women's Health Inc. [ AWHL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.35	12/02/2025		A		314,811		12/02/2025	12/02/2035	Common Stock	314,811	$0	314,811	D

Explanation of Responses:

	/s/ John D. Fraser	12/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Aspira Women's Health (AWHL) disclose?

Aspira Women's Health disclosed a stock option grant to a director, giving the right to buy 314,811 shares of common stock at an exercise price of $0.35 per share.

What is the exercise price of the new Aspira Women's Health (AWHL) stock option?

The stock option granted to the director has an exercise price of $0.35 per share of Aspira Women's Health common stock.

When does the Aspira Women's Health (AWHL) director stock option become exercisable and when does it expire?

The director's stock option becomes exercisable on 12/02/2025 and is scheduled to expire on 12/02/2035.

How many derivative securities does the Aspira Women's Health (AWHL) director own after this transaction?

After the reported transaction, the director beneficially owns 314,811 derivative securities, all in the form of this stock option, held directly.

What role does the reporting person have at Aspira Women's Health (AWHL)?

The reporting person is identified as a Director of Aspira Women's Health Inc. on the form.

Who signed the insider transaction report for Aspira Women's Health (AWHL)?

The insider transaction report is signed by /s/ John D. Fraser as the reporting person on 12/04/2025.